Correlation Between DiaMedica Therapeutics and Dyadic International

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both DiaMedica Therapeutics and Dyadic International at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining DiaMedica Therapeutics and Dyadic International into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between DiaMedica Therapeutics and Dyadic International, you can compare the effects of market volatilities on DiaMedica Therapeutics and Dyadic International and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in DiaMedica Therapeutics with a short position of Dyadic International. Check out your portfolio center. Please also check ongoing floating volatility patterns of DiaMedica Therapeutics and Dyadic International.

Diversification Opportunities for DiaMedica Therapeutics and Dyadic International

-0.72
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between DiaMedica and Dyadic is -0.72. Overlapping area represents the amount of risk that can be diversified away by holding DiaMedica Therapeutics and Dyadic International in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dyadic International and DiaMedica Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DiaMedica Therapeutics are associated (or correlated) with Dyadic International. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dyadic International has no effect on the direction of DiaMedica Therapeutics i.e., DiaMedica Therapeutics and Dyadic International go up and down completely randomly.

Pair Corralation between DiaMedica Therapeutics and Dyadic International

Given the investment horizon of 90 days DiaMedica Therapeutics is expected to generate 0.61 times more return on investment than Dyadic International. However, DiaMedica Therapeutics is 1.64 times less risky than Dyadic International. It trades about 0.15 of its potential returns per unit of risk. Dyadic International is currently generating about -0.01 per unit of risk. If you would invest  401.00  in DiaMedica Therapeutics on July 23, 2024 and sell it today you would earn a total of  33.00  from holding DiaMedica Therapeutics or generate 8.23% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

DiaMedica Therapeutics  vs.  Dyadic International

 Performance 
       Timeline  
DiaMedica Therapeutics 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in DiaMedica Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, DiaMedica Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.
Dyadic International 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Dyadic International has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in November 2024. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

DiaMedica Therapeutics and Dyadic International Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with DiaMedica Therapeutics and Dyadic International

The main advantage of trading using opposite DiaMedica Therapeutics and Dyadic International positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if DiaMedica Therapeutics position performs unexpectedly, Dyadic International can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dyadic International will offset losses from the drop in Dyadic International's long position.
The idea behind DiaMedica Therapeutics and Dyadic International pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Complementary Tools

Fundamental Analysis
View fundamental data based on most recent published financial statements
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Valuation
Check real value of public entities based on technical and fundamental data